INTRODUCTION
Esophageal cancer is the sixth most common cause of cancer related mortality in men, with 3-fold higher rates in men than women (1, 2) . Of the two main histological subtypes (adenocarcinoma and squamous cell carcinoma), the incidence of esophageal adenocarcinoma (EAC) has been rising continuously in Western countries, and accounts for the majority of cases (3) (4) (5) . Despite aggressive treatment, EAC has a 5-year survival of less than 20% (6) . EAC is thought to develop from the metaplastic condition Barrett's esophagus (BE) as a consequence of gastroesophageal reflux disease (GERD) through a metaplasia-dysplasia-adenocarcinoma sequence ( Figure 1A ) (7) (8) (9) .
Currently, BE patients usually undergo endoscopy-biopsy surveillance with the degree of dysplasia assessed by histopathology as a biomarker to monitor risk of neoplastic progression (10) .
Patients diagnosed with high grade dysplasia (BE-HGD) are treated with endoscopic mucosal resection, radiofrequency ablation or surgery, in an attempt to halt further disease progression (10) (11) (12) . The significant cost of endoscopy plus the low annual progression rate to HGD or EAC means that the cost-effectiveness of endoscopic surveillance is questioned at the population level (13) (14) (15) (16) .
Furthermore the evaluation of dysplasia in tissue biopsies by histopathology is prone to interobserver variability and sampling error (17). A less costly and minimally invasive diagnostic procedure is needed for cost-effective screening and surveillance of at-risk populations (18, 19) .
As the first step to developing blood-based EAC diagnostic test, we focused on differential glycosylation of serum glycoproteins during EAC pathogenesis. We established a new glycoprotein biomarker pipeline which couples lectin-based glycoprotein isolation with state-ofthe-art discovery and targeted proteomics (20) (21) (22) (23) . We then applied it to identify and verify changes in lectin binding profile of serum glycoproteins between healthy, BE and EAC patients 7 (22) . Here, we report results from validation in independent cohorts, and evaluation of biomarker panels for surveillance of BE patients.
Figure 1. (A)
Pathogenesis of esophageal adenocarcinoma (EAC) and clinical management of patients during each stage. In response to exposure to gastric and bile acid, non-specialized esophageal epithelium (NSE) converts to Barrett's esophagus (BE), and may progress through low grade dysplasia (LGD) and high grade dysplasia (HGD) stages to EAC. Patients at high risk of BE undergo endoscopic screening to detect asymptomatic metaplastic BE condition. Patients with BE or BE-LGD undergo endoscopy-biopsy surveillance to detect BE-HGD for endoscopic treatments. (B) Workflow of the study. A total of 301 serum samples from two different patient cohorts were subjected to lectin magnetic bead array-coupled multiple reaction monitoring mass spectrometry (LeMBA-MRM-MS). Biomarker candidates for EAC and surveillance were identified by statistical analysis. Tissue expression of top glycoprotein biomarker candidate complement C9 was evaluated by immunohistochemistry.
EXPERIMENTAL PROCEDURES

Clinical cohorts
Ethical approval was obtained from all participating institutions, and all patients provided informed consent to participate in the studies. We investigated two independent cohorts recruited in Australia and the United States of America, respectively. The Australian samples were selected from participants recruited into The Progression of Barrett's Esophagus to Cancer Network Independently, a cross-sectional cohort of 49 serum samples collected at Ochsner Health System, New Orleans, United States were also analyzed [Normal -14, BE -13, Barrett's mucosa which is indefinite for dysplasia (BE-ID) -3, BE-LGD -2, BE-HGD -7, and EAC -10]. Some patients in the Normal group had a history of Barrett's related pathology and received endoscopic treatments. These patients were confirmed to have no Barrett's mucosa by histology at the time of serum collection, hence the normal groups will be called non-specialized epithelium [NSE, epithelium without Barrett's mucosa].
The clinical diagnosis linked to the sample was based on histological examination of biopsies taken at the same endoscopy. The diagnoses were provided to the researcher performing the biomarker measurements to allow batch randomization design for the assay. Serum samples were stored at -80°C, aliquoted, and shipped to the Translational Research Institute, Brisbane on dry ice for this study. Skyline was used for inspecting and processing MRM data (25) . The quality of acquired datasets (Supplemental Table 2A for PROBE-NET cohort and Supplemental Table 2B for Ochsner cohort) were evaluated by % coefficient of variation (% CV) of spiked-in stable isotope-labeled internal standard (SIS) peptides and peptides derived from the spiked-in internal standard protein chicken ovalbumin. The data were normalized using the median intensity of 8 SIS peptides.
Peptide intensities were converted into protein intensity with Pearson correlation coefficient cutoff set at 0.6 (22) . As recently highlighted by others (26) CART) was used to identify a multivariate panel of markers that would discriminate between surveillance outcomes (BE-HGD+EAC vs BE+BE-ID+BE-LGD). The PROBE-NET dataset was used as the training set to develop predictive models, and the Ochsner dataset was used as the validation set. The set of 217 markers that were available in both PROBE-NET and Ochsner datasets was used in the training set, as well as baseline characteristics, including age, gender, and BMI. To avoid overfitting, models were limited to 6, 8, and 10 biomarkers. The prediction formulas derived from PROBE-NET were then applied to the Ochsner dataset to determine sensitivity and specificity in the validation set. 
Immunohistochemical analysis
Immunohistochemical staining was performed on 42 tissue sections collected from 34 patients using anti-C9 primary antibody (Sigma Aldrich #SAB4503059). Detailed immunohistochemistry protocol is described in Supplemental Methods. To confirm the staining specificity, the anti-C9 antibody was neutralized with C9 recombinant protein before application to the slide, as reported in Supplemental Methods and Supplemental Figure 1 . Staining intensities in squamous mucosa, columnar epithelium without intestinal metaplasia, Barrett's esophagus mucosa (with intestinal metaplasia), dysplasia (low and high grade), EAC and inflammatory infiltrate were scored by a specialist gastrointestinal pathologist. Each component, if present in the tissue, was scored separately using a 4 grade assessment of intensity (0 no staining, 1+ weak staining, 2+ moderate staining, 3+ strong staining). Where the staining was non-uniform in a component, the maximum intensity of staining was used for the score, providing at least 10% of the cells of that component stained to this intensity. Due to limited numbers, for statistical analysis, we combined dysplasia with EAC group; similarly, those with 3+ staining in Barrett's mucosa were combined with 2+ staining group. The relationship between histological features and the staining intensity was evaluated using Fisher exact test.
RESULTS
Workflow of this study is depicted in Figure 1B . Table 3 ). Data for the top 10 biomarkers that differentiate EAC from NSE, and EAC from BE in PROBE-NET cohort are shown in Figure 2A and 2B, respectively. Out of these candidates, 16
candidates for EAC vs NSE comparison and 9 candidates for EAC vs BE comparison were also significantly different in the Ochsner cohort, confirming these glycoproteins as validated biomarkers. As illustrated in Figure 2C , 8 validated biomarkers overlap between the two lists.
These biomarkers are potentially most useful, being able to distinguish EAC from NSE and BE.
Interestingly, the 8 biomarkers comprised of different glycosylated forms of 4 proteins, namely, complement C9 (C9), gelsolin (GSN), serum paraoxonase/arylesterase 1 (PON1), serum paraoxonase/lactonase 3 (PON3).
Next we considered BMI as a potential confounding factor for EAC biomarker validation.
Correlation analysis between BMI and biomarker levels in all PROBE-NET samples revealed no substantial correlation (|r|<0.6) (Supplemental Table 4 
Biomarkers for BE surveillance
Having confirmed univariate biomarkers for detection of EAC from NSE and BE in independent cohorts, we next evaluated the ability of serum glycoproteins to be used as a surveillance tool for BE and BE-LGD patients, i.e. to distinguish between patients who require treatment (BE-HGD and EAC) and those who do not (BE, BE-ID and BE-LGD). Eight biomarkers that showed AUROC > 0.6 in a BE surveillance setting for both PROBE-NET and Ochsner cohort Next we sought to generate a multimarker panel for BE surveillance, using the PROBE-NET cohort for modeling and Ochsner cohort for model validation. The minimal panel of six biomarkers showed 0.83 AUROC, 83% specificity and 67% sensitivity for the PROBE-NET cohort, and a moderate specificity of 61% and sensitivity of 63% for the Ochsner cohort ( Table 2 ).
Addition of 4 more biomarkers to the panel increased the AUROC to 0.93, and improved the specificity and sensitivity measures for PROBE-NET, as well as the sensitivity for Ochsner cohort (Table 2 ).
Figure 3. Serum glycoprotein biomarkers for BE surveillance in PROBE-NET and
Ochsner cohorts. Glycoproteins that distinguish patients who require treatment (BE-HGD+EAC) from those who do not require treatment (BE+BE-ID+BE-LGD) with an area under receiver operating characteristic curve (AUROC) value of > 0.6 in both PROBE-NET and Ochsner cohorts are shown. Odds ratio (OR) with 95% Wald confidence intervals, likelihood ratio P values and AUROC values for (A) PROBE-NET cohort and (B) Ochsner cohort. AAL = Aleuria aurantia lectin; AUROC = area under receiver operating characteristic curve; BE = Barrett's esophagus; BE-HGD = BE with high-grade dysplasia; BE-LGD = BE with low-grade dysplasia; C9 = complement C9; CFB = complement factor B; CI = confidence interval; EAC = esophageal adenocarcinoma; EPHA = erythroagglutinin Phaseolus vulgaris; GSN = gelsolin; JAC = jacalin from Artocarpus integrifolia; NPL = Narcissus pseudonarcissus lectin; PON1 = serum paraoxonase/arylesterase 1; PON3 = serum paraoxonase/lactonase 3. 
Complement C9 expression in BE and EAC tissue
In agreement with our previous finding of complement pathway dysregulation in EAC pathogenesis (22), 5 of the 10 glycoprotein biomarker candidates in the final surveillance biomarker panel (Table 2 ) belonged to the complement pathway. As a first step to evaluate alterations of the complement pathway in EAC at a tissue level, we optimized immunohistochemistry staining for the top candidate complement C9. Staining specificity of the method was confirmed by neutralization of the antibody with recombinant C9 protein prior to staining (Supplemental Figure 1) . We then evaluated expression of C9 in esophageal tissue sections from a subset of the Ochsner cohort. As shown in Figure 4A , C9 was detected in BE and EAC, but not squamous esophageal epithelium. Dysplastic BE showed particularly strong staining in the plasma membrane and/or cytoplasm ( Figure 4A ). Strong staining in immune infiltrates served as an expected positive control. Quantitation of staining intensity score against the tissue phenotype ( Figure 4B ) showed statistically significant association between C9 expression levels and histology groups of squamous epithelium, columnar epithelium, Barrett's mucosa, dysplasia/EAC (P<0.001).
Serum complement C9 glycoforms in progressor samples
As an additional evaluation, we examined C9 lectin pull-down levels in samples from PROBE-NET participants who had progressed from BE to BE-LGD (N = 4), BE-LGD to BE- Significant elevation of C9_EPHA and C9_NPL was observed following progression in this small patient cohort ( Figure 5 ).
DISCUSSION
This study advances our previous serum glycoprotein research (22, 23) and provides a critical breakthrough towards developing cost-effective EAC surveillance. Over the years, several studies have been carried out to identify circulatory biomarker candidates to diagnose BEdysplasia-EAC disease spectrum (19, 27) . These studies have explored genetic alterations in cell free circulating DNA (28), serum miRNA changes (29) , circulatory tumor cells (30) , glycan profile alteration in serum (31, 32) , circulatory autoantibodies (against cancer antigens) (33), volatile organic compounds found in breath analysis (34) , metabolic changes in urine (35) , and a panel of Figure 5 . Serum complement C9 (C9) levels in specific lectin-pulldowns in PROBE-NET progressor serum samples. C9 levels in lectin pull-downs are expressed as ratio of intensity of natural peptide LSPIYNLVPVK to stable isotope labeled spiked-in peptide response. The changes in C9 in lectin pull-down samples of participants who progressed from one stage (baseline) to another stage of the disease at follow-up. P value from paired t-test. AAL = Aleuria aurantia lectin; BE = Barrett's esophagus; BE-HGD = BE with high-grade dysplasia; BE-LGD = BE with low-grade dysplasia; C9 = complement C9; EAC = esophageal adenocarcinoma; EPHA = erythroagglutinin Phaseolus vulgaris; JAC = jacalin from Artocarpus integrifolia; NPL = Narcissus pseudonarcissus lectin; SIS = stable isotope standard.
serum proteins (36) as promising diagnostic biomarker candidates for BE and/or EAC. However, none of these biomarker candidates have progressed to from bench to bedside, likely due to the lack of subsequent validation studies in large independent cohort of patients. Here, we have addressed this gap by validating eight serum glycoprotein biomarkers for EAC in two independent patient cohorts including dysplastic samples.
In addition to demonstrating the robustness of our mass spectrometry based glycoproteincentric proteomics workflow for biomarker validation, the current study confirmed our previous finding of complement activation in EAC (22) . The complement system consists of a cascade of circulating proteases that are locally activated leading to the formation of the membrane attack complex on the immunogen and recruitment of phagocytes. Complement components are predominantly expressed and secreted into the plasma by the liver but are also found to be expressed in other tissues (37), but some complement proteins may be expressed by tumor cells (38) . While complement components are primarily involved in mediating innate immune response, recent studies have revealed an apparently paradoxical tumor-promoting role of the complement system (38, 39) . Complement C3 has been reported to play an autocrine role in ovarian and lung cancer tumor growth (40). C5a is elevated in serum of lung cancer patients (41) and increases the invasiveness of C5aR+ tumors (42) . Fucosylated C9 was previously reported to be elevated in the serum of lung cancer patients (43).
Two previous publications reported on complement component changes in BE and EAC. and C9_EPHA for BE surveillance in independent cohorts (Figure 3) . The latter result suggests a pathological change in the secretion, glycosylation, or expression of C9 during the progression of BE to BE-HGD/EAC. Modulation of C9 expression is unlikely to be the mechanism, since we detected strong C9 staining in both BE and BE-HGD tissue. Interestingly, bile (deoxycholic acid) treatment was reported to altered glycosylation and Golgi structure in esophageal epithelial and BE cells, resulting in impaired protein secretion via the classical pathway (46). Hence, C9 may be sequentially regulated by expression level and glycosylation/secretion during BE-EAC progression. Further studies are required to determine the precise molecular mechanisms.
The strengths of this study include the validation of biomarkers in independent cohorts, evaluation of biomarker panel for BE surveillance, and the use of immunohistochemistry to determine the cellular origin of the top serum glycoprotein biomarker. There are several limitations to our study. While our glycoprotein biomarker pipeline allows high-throughput glycoprotein biomarker discovery, the glycosylation site and glycan structural changes are not determined at early stages. Furthermore, the functional consequences of these glycosylation changes in cancer progression also remain to be evaluated. The small number of progressor samples available is a limitation, not only for the current study, but for evaluation of BE/EAC biomarkers in general.
International collaborations and longitudinal cohort sampling are therefore required to advance the search for EAC biomarkers. Finally, the tissue expression of C9 and other candidates also need to be confirmed in a larger number of samples. 
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